Further research is required to clarify the molecular mechanism behind the effect of genistein on hepatic PPARγ in NASH model, such as the activation of JNK and NF-κB signalling pathways, and the expression of PPARγ target genes in the liver. The gene discussed is NFKB1; the disease is metabolic dysfunction-associated steatohepatitis.